董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rick Pauls | 男 | President and Chief Executive Officer, Director | 49 | 87.82万美元 | 未持股 | 2020-12-31 |
| Michael Giuffre | 男 | Independent Director | 65 | 10.26万美元 | 未持股 | 2020-12-31 |
| James Parsons | 男 | Independent Director | 55 | 10.55万美元 | 未持股 | 2020-12-31 |
| Richard Pilnik | 男 | Chairman of the Board and Independent Director | 64 | 14.19万美元 | 未持股 | 2020-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rick Pauls | 男 | President and Chief Executive Officer, Director | 49 | 87.82万美元 | 未持股 | 2020-12-31 |
| Harry Alcorn | 男 | Chief Medical Officer | 64 | 50.91万美元 | 未持股 | 2020-12-31 |
| Sydney Gilman | 男 | Vice President, Regulatory Affairs | 68 | 未披露 | 未持股 | 2020-12-31 |
| Scott Kellen | 男 | Chief Financial Officer and Secretary | 55 | 48.93万美元 | 未持股 | 2020-12-31 |
| Richard Pilnik | 男 | Chairman of the Board and Independent Director | 64 | 14.19万美元 | 未持股 | 2020-12-31 |
董事简历
中英对照 | 中文 | 英文- Rick Pauls
-
Rick Pauls被Diamedica Therapeutics Inc.任命。2010年1月担任总裁兼首席执行官。他曾担任Diamedica Therapeutics Inc.的成员。从2008年4月到2014年7月，他担任董事会主席。2002年2月至2010年1月，他是生命科学风险投资基金CentreStone Ventures Inc.的联合创始人和董事总经理。从2000年1月到2002年1月，他是Centara Corporation(另一家早期风险投资基金)的分析师。从1997年6月到1999年11月，他在通用汽车承兑公司(General Motors acceptance Corporation)工作，专攻资产支持证券化和结构性金融。他曾担任LED Medical Diagnostics, Inc.的独立董事。他持有曼尼托巴大学(the University of Manitoba)的经济学学士学位，以及北达科他州大学(the University of North Dakota)的金融工商管理硕士学位。
Rick Pauls was appointed Diamedica Therapeutics Inc. President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of Diamedica Therapeutics Inc. Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999 Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota. - Rick Pauls被Diamedica Therapeutics Inc.任命。2010年1月担任总裁兼首席执行官。他曾担任Diamedica Therapeutics Inc.的成员。从2008年4月到2014年7月，他担任董事会主席。2002年2月至2010年1月，他是生命科学风险投资基金CentreStone Ventures Inc.的联合创始人和董事总经理。从2000年1月到2002年1月，他是Centara Corporation(另一家早期风险投资基金)的分析师。从1997年6月到1999年11月，他在通用汽车承兑公司(General Motors acceptance Corporation)工作，专攻资产支持证券化和结构性金融。他曾担任LED Medical Diagnostics, Inc.的独立董事。他持有曼尼托巴大学(the University of Manitoba)的经济学学士学位，以及北达科他州大学(the University of North Dakota)的金融工商管理硕士学位。
- Rick Pauls was appointed Diamedica Therapeutics Inc. President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of Diamedica Therapeutics Inc. Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999 Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.
- Michael Giuffre
-
Michael Giuffre，医学博士，自2010年8月起担任董事会成员。自2009年7月起，他担任卡尔加里大学(University of Calgary)心脏科学和儿科的临床教授，并拥有广泛的临床实践、心血管研究和大学教学组合。Giuffre博士积极参与医疗保健交付、医疗领导和生物技术业务部门。从2012年到2019年10月，他担任FoodChek Laboratory(一家用于检测食源性和环境病原体和其他微生物的专利快速和准确食品安全测试的全球开发商和供应商)的首席科学官和总裁。他也是FoodChek Systems Inc.的董事会成员。从2017年11月到2019年10月，他担任FoodChek Systems Inc.的董事会主席。他曾担任加拿大医学协会CMA、加拿大儿童基金会、阿尔伯塔医学协会(AMA)、Can-Cal Resources Ltd、Vacci-Test Corporation、IC2E International Inc.、MedMira Inc.和Brightsquid Dental Inc.的董事会成员。Giuffre博士获得了美国心脏病学会(American Academy of Cardiology)的认证和注册任命和杰出研究员任命。2005年，他被卡尔加里医学协会授予“年度医生”，并于2017年被加拿大皇家内科医生和外科医生学院评为“年度导师”。Giuffre博士也是AMA和卡尔加里和地区医生协会的前主席，也是卡尔加里健康地区董事会的前代表。Giuffre博士拥有细胞和微生物生物学学士学位，分子病毒学博士候选人资格，医学博士和工商管理硕士学位。他是加拿大皇家学院委员会认证的FRCPS，专业包括儿科和儿科心脏病学，并拥有儿科心脏电生理学亚专业。他目前是Avenue Living (AL) Asset Management(加拿大阿尔伯塔私人房地产公司)及其附属公司AL real estate Opportunity Trust和AgriSelect Trust的董事会成员。Giuffre博士目前是加拿大阿尔伯塔省的居民。
Michael Giuffre, M.D. has served as a member of the Board of Directors since August 2010. Since July 2009 Dr. Giuffre has served as a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary and has had an extensive portfolio of clinical practice, cardiovascular research and university teaching. Dr. Giuffre is actively involved in health care delivery, medical leadership and in the biotechnology business sector. From 2012 to October 2019 Dr. Giuffre served as Chief Scientific Officer and President of FoodChek Laboratory, a global developer and provider of proprietary rapid and accurate food safety tests for the detection of foodborne and environmental pathogens and other microorganisms, and also as a member of the board of directors of FoodChek Systems Inc. From November 2017 to October 2019 he served as FoodChek Systems Inc.'s Chairman of the Board. Dr. Giuffre previously served on the board of directors of the Canadian Medical Association CMA, Unicef Canada, the Alberta Medical Association (AMA), Can-Cal Resources Ltd, Vacci-Test Corporation, IC2E International Inc., MedMira Inc. and Brightsquid Dental, Inc. Dr. Giuffre has received a Certified and Registered Appointment and a Distinguished Fellow appointment by the American Academy of Cardiology. In 2005 he was awarded Physician of the Year by the Calgary Medical Society and in 2017 was "Mentor of the Year" for the Royal College of Physicians and Surgeons of Canada. Dr. Giuffre was also a former President of the AMA and the Calgary and Area Physicians Association and also a past representative to the board of the Calgary Health Region. Dr. Giuffre holds a Bachelor of Science in cellular and microbial biology, a Ph.D. candidacy in molecular virology, an M.D. and an M.B.A. He is Canadian Royal College board certified FRCPS in specialties that include Pediatrics and Pediatric Cardiology and has a subspecialty in Pediatric Cardiac Electrophysiology. Dr. Giuffre is currently a member of the board of directors of Avenue Living (AL) Asset Management, a private real estate company in Alberta, Canada and its affiliates, AL Real Estate Opportunity Trust and AgriSelect Trust. Dr. Giuffre is currently a resident of Alberta, Canada. - Michael Giuffre，医学博士，自2010年8月起担任董事会成员。自2009年7月起，他担任卡尔加里大学(University of Calgary)心脏科学和儿科的临床教授，并拥有广泛的临床实践、心血管研究和大学教学组合。Giuffre博士积极参与医疗保健交付、医疗领导和生物技术业务部门。从2012年到2019年10月，他担任FoodChek Laboratory(一家用于检测食源性和环境病原体和其他微生物的专利快速和准确食品安全测试的全球开发商和供应商)的首席科学官和总裁。他也是FoodChek Systems Inc.的董事会成员。从2017年11月到2019年10月，他担任FoodChek Systems Inc.的董事会主席。他曾担任加拿大医学协会CMA、加拿大儿童基金会、阿尔伯塔医学协会(AMA)、Can-Cal Resources Ltd、Vacci-Test Corporation、IC2E International Inc.、MedMira Inc.和Brightsquid Dental Inc.的董事会成员。Giuffre博士获得了美国心脏病学会(American Academy of Cardiology)的认证和注册任命和杰出研究员任命。2005年，他被卡尔加里医学协会授予“年度医生”，并于2017年被加拿大皇家内科医生和外科医生学院评为“年度导师”。Giuffre博士也是AMA和卡尔加里和地区医生协会的前主席，也是卡尔加里健康地区董事会的前代表。Giuffre博士拥有细胞和微生物生物学学士学位，分子病毒学博士候选人资格，医学博士和工商管理硕士学位。他是加拿大皇家学院委员会认证的FRCPS，专业包括儿科和儿科心脏病学，并拥有儿科心脏电生理学亚专业。他目前是Avenue Living (AL) Asset Management(加拿大阿尔伯塔私人房地产公司)及其附属公司AL real estate Opportunity Trust和AgriSelect Trust的董事会成员。Giuffre博士目前是加拿大阿尔伯塔省的居民。
- Michael Giuffre, M.D. has served as a member of the Board of Directors since August 2010. Since July 2009 Dr. Giuffre has served as a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary and has had an extensive portfolio of clinical practice, cardiovascular research and university teaching. Dr. Giuffre is actively involved in health care delivery, medical leadership and in the biotechnology business sector. From 2012 to October 2019 Dr. Giuffre served as Chief Scientific Officer and President of FoodChek Laboratory, a global developer and provider of proprietary rapid and accurate food safety tests for the detection of foodborne and environmental pathogens and other microorganisms, and also as a member of the board of directors of FoodChek Systems Inc. From November 2017 to October 2019 he served as FoodChek Systems Inc.'s Chairman of the Board. Dr. Giuffre previously served on the board of directors of the Canadian Medical Association CMA, Unicef Canada, the Alberta Medical Association (AMA), Can-Cal Resources Ltd, Vacci-Test Corporation, IC2E International Inc., MedMira Inc. and Brightsquid Dental, Inc. Dr. Giuffre has received a Certified and Registered Appointment and a Distinguished Fellow appointment by the American Academy of Cardiology. In 2005 he was awarded Physician of the Year by the Calgary Medical Society and in 2017 was "Mentor of the Year" for the Royal College of Physicians and Surgeons of Canada. Dr. Giuffre was also a former President of the AMA and the Calgary and Area Physicians Association and also a past representative to the board of the Calgary Health Region. Dr. Giuffre holds a Bachelor of Science in cellular and microbial biology, a Ph.D. candidacy in molecular virology, an M.D. and an M.B.A. He is Canadian Royal College board certified FRCPS in specialties that include Pediatrics and Pediatric Cardiology and has a subspecialty in Pediatric Cardiac Electrophysiology. Dr. Giuffre is currently a member of the board of directors of Avenue Living (AL) Asset Management, a private real estate company in Alberta, Canada and its affiliates, AL Real Estate Opportunity Trust and AgriSelect Trust. Dr. Giuffre is currently a resident of Alberta, Canada.
- James Parsons
-
James Parsons，自2015年10月起担任董事会成员。此前，从2010年10月到2014年5月，他担任Diamedica Therapeutics Inc.的财务副总裁。自2011年8月起，他担任Trillium Therapeutics Inc.(纳斯达克上市的免疫肿瘤公司)的首席财务官和公司秘书。他担任Sernova Corp.(在TSX Venture Exchange上市)的董事会成员和审计委员会主席。自2000年以来，他一直担任生命科学行业的首席财务官，具有治疗学、诊断和设备方面的经验。他持有the University of Waterloo的会计硕士学位，是一名特许职业会计师和特许会计师。Parsons先生是加拿大安大略省的居民。
James Parsons has been the Chief Financial Officer of Trillium since August 25 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Therapeutics, Inc.As Chief Financial Officer, Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration. - James Parsons，自2015年10月起担任董事会成员。此前，从2010年10月到2014年5月，他担任Diamedica Therapeutics Inc.的财务副总裁。自2011年8月起，他担任Trillium Therapeutics Inc.(纳斯达克上市的免疫肿瘤公司)的首席财务官和公司秘书。他担任Sernova Corp.(在TSX Venture Exchange上市)的董事会成员和审计委员会主席。自2000年以来，他一直担任生命科学行业的首席财务官，具有治疗学、诊断和设备方面的经验。他持有the University of Waterloo的会计硕士学位，是一名特许职业会计师和特许会计师。Parsons先生是加拿大安大略省的居民。
- James Parsons has been the Chief Financial Officer of Trillium since August 25 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Therapeutics, Inc.As Chief Financial Officer, Mr. Parsons is responsible for financial and risk management, investor relations, corporate governance and administration.
- Richard Pilnik
-
Richard Pilnik于2009年7月被任命为Elan董事。在Eli Lilly & Company任职的25年，Pilnik担任过多个领导职位，最近的职位是担任副总裁和首席营销官，负责商业战略、市场研究和医疗营销。Pilnik现任 Quintiles Commercial Solutions（制药服务领域的全球领先者）执行副总裁和总裁。Pilnik持有Duke University文学学士学位以及Northwestern University Kellogg管理学院工商管理硕士学位。
Richard Pilnik has served as a member of the Board of Directors since May 2009. Mr. Pilnik serves as Diamedica Therapeutics Inc. Chairman of the Board. Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc., a medical device company, since May 2017. From December 2015 to November 2017 he served as a member of the board of directors of Chiltern International Limited, a private leading mid-tier Clinical Research Organization, and was Chairman of the Board from April 2016 to November 2017. Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company, a pharmaceutical company, and Quintiles Transnational Corp., a global pioneer in pharmaceutical services. From April 2009 to June 2014 he served as Executive Vice President and President of Quintiles Commercial Solutions, an outsDiamedica Therapeutics Inc.cing business to over 70 pharma and biotech companies. Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions, most recently as Group Vice President and Chief Marketing Officer from May 2006 to July 2008. He was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction. From December 2000 to May 2006 Mr. Pilnik served as President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States, a regional organization of former Soviet Republics, and oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik currently serves on the board of directors of Vigor Medical Systems, Inc., NuSirt, an early-stage biopharma, and BIAL Farma, a Portuguese pharmaceutical company. Mr. Pilnik is an Emeritus Board Member of Duke University Fuqua School of Business. Mr. Pilnik previously served on the board of directors of Elan Pharmaceuticals, Chiltern International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation. Mr. Pilnik holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. Mr. Pilnik is a resident of Florida, USA. - Richard Pilnik于2009年7月被任命为Elan董事。在Eli Lilly & Company任职的25年，Pilnik担任过多个领导职位，最近的职位是担任副总裁和首席营销官，负责商业战略、市场研究和医疗营销。Pilnik现任 Quintiles Commercial Solutions（制药服务领域的全球领先者）执行副总裁和总裁。Pilnik持有Duke University文学学士学位以及Northwestern University Kellogg管理学院工商管理硕士学位。
- Richard Pilnik has served as a member of the Board of Directors since May 2009. Mr. Pilnik serves as Diamedica Therapeutics Inc. Chairman of the Board. Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc., a medical device company, since May 2017. From December 2015 to November 2017 he served as a member of the board of directors of Chiltern International Limited, a private leading mid-tier Clinical Research Organization, and was Chairman of the Board from April 2016 to November 2017. Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company, a pharmaceutical company, and Quintiles Transnational Corp., a global pioneer in pharmaceutical services. From April 2009 to June 2014 he served as Executive Vice President and President of Quintiles Commercial Solutions, an outsDiamedica Therapeutics Inc.cing business to over 70 pharma and biotech companies. Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions, most recently as Group Vice President and Chief Marketing Officer from May 2006 to July 2008. He was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction. From December 2000 to May 2006 Mr. Pilnik served as President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States, a regional organization of former Soviet Republics, and oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik currently serves on the board of directors of Vigor Medical Systems, Inc., NuSirt, an early-stage biopharma, and BIAL Farma, a Portuguese pharmaceutical company. Mr. Pilnik is an Emeritus Board Member of Duke University Fuqua School of Business. Mr. Pilnik previously served on the board of directors of Elan Pharmaceuticals, Chiltern International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation. Mr. Pilnik holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. Mr. Pilnik is a resident of Florida, USA.
高管简历
中英对照 | 中文 | 英文- Rick Pauls
Rick Pauls被Diamedica Therapeutics Inc.任命。2010年1月担任总裁兼首席执行官。他曾担任Diamedica Therapeutics Inc.的成员。从2008年4月到2014年7月，他担任董事会主席。2002年2月至2010年1月，他是生命科学风险投资基金CentreStone Ventures Inc.的联合创始人和董事总经理。从2000年1月到2002年1月，他是Centara Corporation(另一家早期风险投资基金)的分析师。从1997年6月到1999年11月，他在通用汽车承兑公司(General Motors acceptance Corporation)工作，专攻资产支持证券化和结构性金融。他曾担任LED Medical Diagnostics, Inc.的独立董事。他持有曼尼托巴大学(the University of Manitoba)的经济学学士学位，以及北达科他州大学(the University of North Dakota)的金融工商管理硕士学位。
Rick Pauls was appointed Diamedica Therapeutics Inc. President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of Diamedica Therapeutics Inc. Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999 Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.- Rick Pauls被Diamedica Therapeutics Inc.任命。2010年1月担任总裁兼首席执行官。他曾担任Diamedica Therapeutics Inc.的成员。从2008年4月到2014年7月，他担任董事会主席。2002年2月至2010年1月，他是生命科学风险投资基金CentreStone Ventures Inc.的联合创始人和董事总经理。从2000年1月到2002年1月，他是Centara Corporation(另一家早期风险投资基金)的分析师。从1997年6月到1999年11月，他在通用汽车承兑公司(General Motors acceptance Corporation)工作，专攻资产支持证券化和结构性金融。他曾担任LED Medical Diagnostics, Inc.的独立董事。他持有曼尼托巴大学(the University of Manitoba)的经济学学士学位，以及北达科他州大学(the University of North Dakota)的金融工商管理硕士学位。
- Rick Pauls was appointed Diamedica Therapeutics Inc. President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of Diamedica Therapeutics Inc. Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica, Mr. Pauls was the Co-Founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund, from February 2002 until January 2010. Mr. Pauls was an analyst for Centara Corporation, another early stage venture capital fund, from January 2000 until January 2002. From June 1997 until November 1999 Mr. Pauls worked for General Motors Acceptation Corporation specializing in asset-backed securitization and structured finance. Mr. Pauls previously served as an independent member of the board of directors of LED Medical Diagnostics, Inc. Mr. Pauls received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.
- Harry Alcorn
Harry Alcorn Pharm.D.被Diamedica Therapeutics Inc.任命。2018年8月担任首席医务官。1997年10月至2018年6月，他担任DaVita Clinical Research DCR(一家为制药和生物技术公司提供临床研究服务的公司)的首席科学官。在DCR任职期间，Alcorn博士负责临床研究运营，包括早期临床和后期研究服务的形成和管理。奥尔康博士还创立了美国肾脏网络，这是美国第一个一期肾脏研究网站网络。Alcorn博士开发了DCR的临床试验现场管理组织。他还担任DCR的执行董事、药剂师和研究员。在此期间，从2013年1月到2014年12月，他还担任the Association of Clinical Pharmacology Units(1期临床试验站点的协会)的董事会成员。Alcorn博士拥有超过30年的临床研究经验，在公共和私人生物技术和制药公司进行肾脏、肝脏和心血管疾病的研究。Alcorn博士曾撰写和咨询多个方案的开发，并担任多个研究的首席研究员或副研究员，其中一些研究向FDA提交了研究设计和结果。目前，他在明尼苏达大学、克莱顿大学、内布拉斯加大学医学中心、弗吉尼亚联邦大学和丹佛科罗拉多大学担任临床教员。Alcorn博士毕业于Creighton University，获得药剂学学士学位，随后在University of Nebraska Medical Center获得药剂学博士学位。
Harry Alcorn, Pharm.D. was appointed Diamedica Therapeutics Inc. Chief Medical Officer in August 2018. Prior to joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer at DaVita Clinical Research DCR, a company that provides clinical research services for Pharmaceutical and Biotech companies, from October 1997 to June 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including the formation and management of the early clinical and late phase research services. Dr. Alcorn also founded the U.S. Renal Network, the first network of Phase 1 renal research sites in the United States. Dr. Alcorn developed DCR's site management organization for clinical trials. Dr. Alcorn also served as an Executive Director, a Pharmacist and an Investigator at DCR. During this time, from January 2013 to December 2014 he also served on the Board of Directors for the Association of Clinical Pharmacology Units, an association of Phase 1 clinical trial sites. Dr. Alcorn has over 30 years of clinical research experience working with biotech and pharmaceutical companies, both public and private, in conducting research in renal, hepatic and cardiovascular disease. Dr. Alcorn has written and consulted on the development of several protocols and has served as Principal Investigator or Sub Investigator in numerous studies and, for several of these studies, presented study design and results to the FDA. Currently he holds clinical faculty appointments with the University of Minnesota, Creighton University, University of Nebraska Medical Center, Virginia Commonwealth and the University of Colorado, Denver. Dr. Alcorn graduated from Creighton University with a Bachelor of Pharmacy and went on to earn his Doctor of Pharmacy degree from University of Nebraska Medical Center.- Harry Alcorn Pharm.D.被Diamedica Therapeutics Inc.任命。2018年8月担任首席医务官。1997年10月至2018年6月，他担任DaVita Clinical Research DCR(一家为制药和生物技术公司提供临床研究服务的公司)的首席科学官。在DCR任职期间，Alcorn博士负责临床研究运营，包括早期临床和后期研究服务的形成和管理。奥尔康博士还创立了美国肾脏网络，这是美国第一个一期肾脏研究网站网络。Alcorn博士开发了DCR的临床试验现场管理组织。他还担任DCR的执行董事、药剂师和研究员。在此期间，从2013年1月到2014年12月，他还担任the Association of Clinical Pharmacology Units(1期临床试验站点的协会)的董事会成员。Alcorn博士拥有超过30年的临床研究经验，在公共和私人生物技术和制药公司进行肾脏、肝脏和心血管疾病的研究。Alcorn博士曾撰写和咨询多个方案的开发，并担任多个研究的首席研究员或副研究员，其中一些研究向FDA提交了研究设计和结果。目前，他在明尼苏达大学、克莱顿大学、内布拉斯加大学医学中心、弗吉尼亚联邦大学和丹佛科罗拉多大学担任临床教员。Alcorn博士毕业于Creighton University，获得药剂学学士学位，随后在University of Nebraska Medical Center获得药剂学博士学位。
- Harry Alcorn, Pharm.D. was appointed Diamedica Therapeutics Inc. Chief Medical Officer in August 2018. Prior to joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer at DaVita Clinical Research DCR, a company that provides clinical research services for Pharmaceutical and Biotech companies, from October 1997 to June 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including the formation and management of the early clinical and late phase research services. Dr. Alcorn also founded the U.S. Renal Network, the first network of Phase 1 renal research sites in the United States. Dr. Alcorn developed DCR's site management organization for clinical trials. Dr. Alcorn also served as an Executive Director, a Pharmacist and an Investigator at DCR. During this time, from January 2013 to December 2014 he also served on the Board of Directors for the Association of Clinical Pharmacology Units, an association of Phase 1 clinical trial sites. Dr. Alcorn has over 30 years of clinical research experience working with biotech and pharmaceutical companies, both public and private, in conducting research in renal, hepatic and cardiovascular disease. Dr. Alcorn has written and consulted on the development of several protocols and has served as Principal Investigator or Sub Investigator in numerous studies and, for several of these studies, presented study design and results to the FDA. Currently he holds clinical faculty appointments with the University of Minnesota, Creighton University, University of Nebraska Medical Center, Virginia Commonwealth and the University of Colorado, Denver. Dr. Alcorn graduated from Creighton University with a Bachelor of Pharmacy and went on to earn his Doctor of Pharmacy degree from University of Nebraska Medical Center.
- Sydney Gilman
Sydney Gilman博士获Diamedica Therapeutics Inc.任命。2019年11月，担任监管事务副总裁。他目前是Trident Rx Consulting Services LLC（监管咨询公司）的创始人和总裁（2004年1月以来）。Gilman博士是前FDA化学审稿人。他在FDA任职6年，任职于药物评估和研究中心（Center for Drug Evaluation and Research）的多个CDER治疗药物部门，从事生物制品和设备方面的咨询工作。Gilman博士还在制药行业拥有额外的20年经验，从高级科学家到董事到副总裁。他在Loyola College获得理学学士学位，在the University of Pittsburgh获得有机化学博士学位。
Sydney Gilman, Ph.D. was appointed Diamedica Therapeutics Inc. Vice President, Regulatory Affairs in November 2019. Dr. Gilman is currently the founder and President of Trident Rx Consulting Services LLC, a regulatory consulting firm, a position he has held since January 2004. Dr. Gilman is a former FDA Chemistry reviewer. He spent six years at the FDA in various CDER Therapeutic Drug Divisions of the Center for Drug Evaluation and Research with consulting ties to both Biologics and Devices. Dr. Gilman also has an additional 20 years of experience in the pharmaceutical industry in positions ranging from Senior Scientist to Director to Vice President responsibilities. He earned his Bachelor of Science from Loyola College and a Ph.D. in Organic Chemistry from the University of Pittsburgh.- Sydney Gilman博士获Diamedica Therapeutics Inc.任命。2019年11月，担任监管事务副总裁。他目前是Trident Rx Consulting Services LLC（监管咨询公司）的创始人和总裁（2004年1月以来）。Gilman博士是前FDA化学审稿人。他在FDA任职6年，任职于药物评估和研究中心（Center for Drug Evaluation and Research）的多个CDER治疗药物部门，从事生物制品和设备方面的咨询工作。Gilman博士还在制药行业拥有额外的20年经验，从高级科学家到董事到副总裁。他在Loyola College获得理学学士学位，在the University of Pittsburgh获得有机化学博士学位。
- Sydney Gilman, Ph.D. was appointed Diamedica Therapeutics Inc. Vice President, Regulatory Affairs in November 2019. Dr. Gilman is currently the founder and President of Trident Rx Consulting Services LLC, a regulatory consulting firm, a position he has held since January 2004. Dr. Gilman is a former FDA Chemistry reviewer. He spent six years at the FDA in various CDER Therapeutic Drug Divisions of the Center for Drug Evaluation and Research with consulting ties to both Biologics and Devices. Dr. Gilman also has an additional 20 years of experience in the pharmaceutical industry in positions ranging from Senior Scientist to Director to Vice President responsibilities. He earned his Bachelor of Science from Loyola College and a Ph.D. in Organic Chemistry from the University of Pittsburgh.
- Scott Kellen
Scott Kellen，2010年加入本公司，担任首席财务官、财务副总裁、秘书；2012年3月，他成为本公司的首席运营官。2007-2009，他担任Transoma Medical的财务总监；2009年2月1日至2009年5月1日，担任其首席财务官；上述任职也包括首次公开发行的准备期间，但由于市场环境的恶化，2008年2月上市申请被撤销。2005-2007，在ev3 Inc的首次公开发行和后续发行期间，他担任ev3 Inc的企业财务总监。2003-2005，他担任Deloitte & Touche, LLP（现Deloitte LLP）的高级审计经理，为中等规模的上市公司提供服务。他在医疗器械行业工作了近20年，接触的是生产II类和III类器械的早期及成长型公司。1987年，他的职业生涯始于Deloitte & Touche 。他获得了University of South Dakota的工商管理学士学位，是一名非执业注册会计师。
Scott Kellen joined DiaMedica as Diamedica Therapeutics Inc. Vice President of Finance in January 2018 and was appointed Diamedica Therapeutics Inc. Chief Financial Officer and Secretary in April 2018. Prior to joining DiaMedica, Mr. Kellen served as Vice President and Chief Financial Officer of Panbela Therapeutics, Inc., formerly known as Sun BioPharma, Inc., a publicly-traded clinical stage drug development company, from October 2015 until April 2018. From February 2010 to September 2015 Mr. Kellen served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly-traded medical device company, and became Chief Operating Officer of Kips Bay in March 2012. From November 2007 to May 2009 Mr. Kellen served as Finance Director of Transoma Medical, Inc. From 2005 to October 2007 Mr. Kellen served as Corporate Controller of ev3 Inc. From March 2003 to April 2005 Mr. Kellen served as Senior Manager, Audit and Advisory Services of Deloitte & Touche, LLP. Altogether, Mr. Kellen has spent more than 25 years in the life sciences industry, focusing on publicly traded early stage and growth companies. Mr. Kellen has a Bachelor of Science degree in Business Administration from the University of South Dakota and is a Certified Public Accountant inactive.- Scott Kellen，2010年加入本公司，担任首席财务官、财务副总裁、秘书；2012年3月，他成为本公司的首席运营官。2007-2009，他担任Transoma Medical的财务总监；2009年2月1日至2009年5月1日，担任其首席财务官；上述任职也包括首次公开发行的准备期间，但由于市场环境的恶化，2008年2月上市申请被撤销。2005-2007，在ev3 Inc的首次公开发行和后续发行期间，他担任ev3 Inc的企业财务总监。2003-2005，他担任Deloitte & Touche, LLP（现Deloitte LLP）的高级审计经理，为中等规模的上市公司提供服务。他在医疗器械行业工作了近20年，接触的是生产II类和III类器械的早期及成长型公司。1987年，他的职业生涯始于Deloitte & Touche 。他获得了University of South Dakota的工商管理学士学位，是一名非执业注册会计师。
- Scott Kellen joined DiaMedica as Diamedica Therapeutics Inc. Vice President of Finance in January 2018 and was appointed Diamedica Therapeutics Inc. Chief Financial Officer and Secretary in April 2018. Prior to joining DiaMedica, Mr. Kellen served as Vice President and Chief Financial Officer of Panbela Therapeutics, Inc., formerly known as Sun BioPharma, Inc., a publicly-traded clinical stage drug development company, from October 2015 until April 2018. From February 2010 to September 2015 Mr. Kellen served as Chief Financial Officer and Secretary of Kips Bay Medical, Inc., a publicly-traded medical device company, and became Chief Operating Officer of Kips Bay in March 2012. From November 2007 to May 2009 Mr. Kellen served as Finance Director of Transoma Medical, Inc. From 2005 to October 2007 Mr. Kellen served as Corporate Controller of ev3 Inc. From March 2003 to April 2005 Mr. Kellen served as Senior Manager, Audit and Advisory Services of Deloitte & Touche, LLP. Altogether, Mr. Kellen has spent more than 25 years in the life sciences industry, focusing on publicly traded early stage and growth companies. Mr. Kellen has a Bachelor of Science degree in Business Administration from the University of South Dakota and is a Certified Public Accountant inactive.
- Richard Pilnik
Richard Pilnik于2009年7月被任命为Elan董事。在Eli Lilly & Company任职的25年，Pilnik担任过多个领导职位，最近的职位是担任副总裁和首席营销官，负责商业战略、市场研究和医疗营销。Pilnik现任 Quintiles Commercial Solutions（制药服务领域的全球领先者）执行副总裁和总裁。Pilnik持有Duke University文学学士学位以及Northwestern University Kellogg管理学院工商管理硕士学位。
Richard Pilnik has served as a member of the Board of Directors since May 2009. Mr. Pilnik serves as Diamedica Therapeutics Inc. Chairman of the Board. Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc., a medical device company, since May 2017. From December 2015 to November 2017 he served as a member of the board of directors of Chiltern International Limited, a private leading mid-tier Clinical Research Organization, and was Chairman of the Board from April 2016 to November 2017. Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company, a pharmaceutical company, and Quintiles Transnational Corp., a global pioneer in pharmaceutical services. From April 2009 to June 2014 he served as Executive Vice President and President of Quintiles Commercial Solutions, an outsDiamedica Therapeutics Inc.cing business to over 70 pharma and biotech companies. Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions, most recently as Group Vice President and Chief Marketing Officer from May 2006 to July 2008. He was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction. From December 2000 to May 2006 Mr. Pilnik served as President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States, a regional organization of former Soviet Republics, and oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik currently serves on the board of directors of Vigor Medical Systems, Inc., NuSirt, an early-stage biopharma, and BIAL Farma, a Portuguese pharmaceutical company. Mr. Pilnik is an Emeritus Board Member of Duke University Fuqua School of Business. Mr. Pilnik previously served on the board of directors of Elan Pharmaceuticals, Chiltern International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation. Mr. Pilnik holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. Mr. Pilnik is a resident of Florida, USA.- Richard Pilnik于2009年7月被任命为Elan董事。在Eli Lilly & Company任职的25年，Pilnik担任过多个领导职位，最近的职位是担任副总裁和首席营销官，负责商业战略、市场研究和医疗营销。Pilnik现任 Quintiles Commercial Solutions（制药服务领域的全球领先者）执行副总裁和总裁。Pilnik持有Duke University文学学士学位以及Northwestern University Kellogg管理学院工商管理硕士学位。
- Richard Pilnik has served as a member of the Board of Directors since May 2009. Mr. Pilnik serves as Diamedica Therapeutics Inc. Chairman of the Board. Mr. Pilnik has served as the President and member of the board of directors of Vigor Medical Services, Inc., a medical device company, since May 2017. From December 2015 to November 2017 he served as a member of the board of directors of Chiltern International Limited, a private leading mid-tier Clinical Research Organization, and was Chairman of the Board from April 2016 to November 2017. Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company, a pharmaceutical company, and Quintiles Transnational Corp., a global pioneer in pharmaceutical services. From April 2009 to June 2014 he served as Executive Vice President and President of Quintiles Commercial Solutions, an outsDiamedica Therapeutics Inc.cing business to over 70 pharma and biotech companies. Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions, most recently as Group Vice President and Chief Marketing Officer from May 2006 to July 2008. He was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction. From December 2000 to May 2006 Mr. Pilnik served as President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States, a regional organization of former Soviet Republics, and oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America. Mr. Pilnik currently serves on the board of directors of Vigor Medical Systems, Inc., NuSirt, an early-stage biopharma, and BIAL Farma, a Portuguese pharmaceutical company. Mr. Pilnik is an Emeritus Board Member of Duke University Fuqua School of Business. Mr. Pilnik previously served on the board of directors of Elan Pharmaceuticals, Chiltern International, the largest mid-size Clinical Research Organization, and Certara, L.P., a private biotech company focused on drug development modeling and biosimulation. Mr. Pilnik holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University. Mr. Pilnik is a resident of Florida, USA.